|
SG2013013339A
(en)
*
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
CA2532067C
(en)
|
2003-07-24 |
2010-12-21 |
Stephen Douglas Barrett |
N-methyle-substituted benzamidazoles
|
|
US7144907B2
(en)
*
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7538120B2
(en)
*
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
PT1673349E
(pt)
|
2003-09-22 |
2010-09-28 |
S Bio Pte Ltd |
Derivados benzimidazole: preparação e aplicações farmacêuticas
|
|
CA2546353A1
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Bicyclic inhibitors of mek and methods of use thereof
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7732616B2
(en)
*
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
CA2546754A1
(en)
*
|
2003-11-21 |
2005-06-09 |
Array Biopharma Inc. |
Akt protein kinase inhibitors
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
MX2007004781A
(es)
|
2004-10-20 |
2007-05-11 |
Applied Research Systems |
Derivados de 3-arilamino piridina.
|
|
JP2008521858A
(ja)
*
|
2004-12-01 |
2008-06-26 |
ラボラトワール セローノ ソシエテ アノニム |
過増殖性疾患を処置するための［１，２，４］トリアゾロ［４，３−ａ］ピリジン誘導体
|
|
SG177981A1
(en)
|
2005-05-18 |
2012-02-28 |
Array Biopharma Inc |
4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
|
|
US8039637B2
(en)
|
2005-06-23 |
2011-10-18 |
Array Biopharma Inc. |
Process for preparing benzimidazole compounds
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
EP1966155A1
(en)
*
|
2005-12-21 |
2008-09-10 |
AstraZeneca AB |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
EP2049500B1
(en)
|
2006-07-06 |
2011-09-07 |
Array Biopharma, Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
|
US8329701B2
(en)
|
2006-07-06 |
2012-12-11 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as AKT protein kinase inhibitors
|
|
ES2528797T3
(es)
*
|
2006-08-21 |
2015-02-12 |
Genentech, Inc. |
Compuestos de aza-benzotiofenilo y métodos de uso
|
|
ES2376771T3
(es)
*
|
2006-08-21 |
2012-03-16 |
Genentech, Inc. |
Compuestos aza-benzofuranilo y métodos de utilización
|
|
ZA200901009B
(en)
*
|
2006-08-21 |
2010-05-26 |
Genentech Inc |
Aza-benzothiophenyl compounds and methods of use
|
|
WO2008076415A1
(en)
|
2006-12-14 |
2008-06-26 |
Exelixis, Inc. |
Methods of using mek inhibitors
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
JP5580735B2
(ja)
|
2007-06-12 |
2014-08-27 |
ジェネンテック， インコーポレイテッド |
Ｎ−置換アザインドール類及び使用方法
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
CN101918373B
(zh)
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CN103396409B
(zh)
|
2007-07-05 |
2015-03-11 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
WO2009064675A1
(en)
|
2007-11-12 |
2009-05-22 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
PT2231662E
(pt)
|
2007-12-19 |
2011-09-12 |
Genentech Inc |
8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
|
|
AU2008343065B2
(en)
*
|
2007-12-19 |
2012-04-05 |
Genentech, Inc. |
5-anilinoimidazopyridines and methods of use
|
|
NZ586575A
(en)
|
2007-12-21 |
2012-03-30 |
Genentech Inc |
Azaindolizines and methods of use
|
|
US8853216B2
(en)
|
2008-01-09 |
2014-10-07 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
|
NZ586346A
(en)
|
2008-01-09 |
2012-02-24 |
Array Biopharma Inc |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
RU2509078C2
(ru)
|
2008-07-01 |
2014-03-10 |
Дженентек, Инк. |
Бициклические гетероциклы в качестве ингибиторов киназы мек
|
|
MX2010014565A
(es)
*
|
2008-07-01 |
2011-03-04 |
Genentech Inc |
Isoindolona y metodos de uso.
|
|
UA107183C2
(uk)
|
2008-08-04 |
2014-12-10 |
|
Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
EP2370568B1
(en)
|
2008-12-10 |
2017-07-19 |
Dana-Farber Cancer Institute, Inc. |
Mek mutations conferring resistance to mek inhibitors
|
|
US20120263714A1
(en)
|
2009-10-21 |
2012-10-18 |
Bayer Intellectual Property Gmbh |
Substituted halophenoxybenzamide derivatives
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
EP3028699B1
(en)
|
2010-02-25 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
CN103038364A
(zh)
|
2010-03-09 |
2013-04-10 |
达纳－法伯癌症研究所公司 |
诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
|
|
JP5719028B2
(ja)
|
2010-10-06 |
2015-05-13 |
グラクソスミスクライン エルエルシー |
Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体
|
|
CN103282351A
(zh)
|
2010-10-29 |
2013-09-04 |
拜耳知识产权有限责任公司 |
取代的苯氧基吡啶
|
|
KR102021157B1
(ko)
|
2011-04-01 |
2019-09-11 |
제넨테크, 인크. |
Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
|
|
TR201815685T4
(tr)
|
2011-04-01 |
2018-11-21 |
Genentech Inc |
Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
|
|
ES2597052T3
(es)
|
2011-05-25 |
2017-01-13 |
Université Paris Descartes |
Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
CN103204827B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
|
|
US20150141470A1
(en)
|
2012-05-08 |
2015-05-21 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
|
|
AU2013269809B2
(en)
|
2012-05-31 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
|
|
MA38085B1
(fr)
|
2012-10-12 |
2018-11-30 |
Exelixis Inc |
Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
|
|
UA118846C2
(uk)
|
2013-03-21 |
2019-03-25 |
Новартіс Аг |
Комбінована терапія
|
|
EP3043822A1
(en)
|
2013-09-11 |
2016-07-20 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Compositions for preparing cardiomyocytes
|
|
CN105384754B
(zh)
*
|
2014-09-02 |
2018-04-20 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
|
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
CN111646946A
(zh)
*
|
2017-11-14 |
2020-09-11 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的苯并咪唑化合物及包含该化合物的组合物
|
|
US20220143049A1
(en)
|
2019-03-21 |
2022-05-12 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
EP4346826A4
(en)
|
2021-05-27 |
2025-04-30 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|